×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| HESTER BIOSCIENCES LTD. | 644.36 | 78.38 | 634.9 | 9.21 | 1,811 | 48.2 |
| Tarsons Products Limited | 758.6 | 35.7 | 712.79 | 0.67 | 1706 | 62.0 |
| BLISS GVS PHARMA LTD. | 1739.57 | 210.53 | 1633.64 | 1.98 | 1623 | 15.2 |
Hester Biosciences Ltd, with Security Code 524669, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60.7 | 80.3 | 66.4 | 65.5 | 72.9 | 73.5 | 73.5 | 62.8 | 76.7 | 63.5 |
| Expenses | 49.8 | 69.0 | 54.4 | 53.9 | 60.5 | 60.0 | 58.8 | 53.8 | 62.9 | 51.1 |
| Operating Profit | 10.9 | 11.4 | 12.0 | 11.6 | 12.4 | 13.5 | 14.7 | 9.0 | 13.7 | 12.4 |
| OPM % | 17.99% | 14.15% | 18.05% | 17.66% | 17.04% | 18.37% | 20.04% | 14.35% | 17.93% | 19.55% |
| Other Income | 1.0 | 0.9 | 1.2 | 1.0 | 1.2 | 1.1 | 1.3 | 1.3 | 1.1 | 0.9 |
| Interest | 0.3 | 0.9 | 1.5 | 1.4 | 1.3 | 1.1 | 1.4 | 1.6 | 1.2 | 0.9 |
| Depreciation | 2.6 | 2.5 | 2.6 | 2.6 | 2.1 | 2.1 | 2.2 | 2.2 | 2.0 | 2.2 |
| Profit before tax | 8.9 | 8.7 | 9.2 | 8.6 | 10.2 | 11.3 | 12.5 | 6.5 | 11.5 | 10.3 |
| Tax % | -29.6% | -25.9% | -26% | -24.8% | -27.3% | 25.4% | -25.2% | -31.6% | -15.7% | 23.8% |
| Net Profit | 6.3 | 6.5 | 6.8 | 6.5 | 7.4 | 8.4 | 9.3 | 4.4 | 9.6 | 7.8 |
| EPS in Rs | 7.36 | 7.61 | 7.97 | 7.61 | 8.74 | 9.91 | 10.97 | 5.22 | 0 | 9.21 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.9 | 67.3 | 87.9 | 70.5 | 67.0 | 79.3 | 82.3 | 83.7 | 63.2 | 81.9 |
| Expenses | 56.2 | 55.6 | 73.5 | 57.2 | 56.8 | 63.3 | 64.6 | 64.5 | 50.5 | 62.7 |
| Operating Profit | 18.8 | 11.7 | 14.4 | 13.2 | 10.2 | 15.9 | 17.7 | 19.2 | 12.7 | 19.2 |
| OPM % | 25.03% | 17.35% | 16.35% | 18.76% | 15.16% | 20.09% | 21.45% | 22.89% | 20.07% | 23.46% |
| Other Income | 4.4 | 3.2 | 1.1 | 4.4 | 1.0 | 4.1 | 1.2 | 1.8 | 7.8 | -7.0 |
| Interest | 3.9 | 1.4 | 2.6 | 8.1 | 2.2 | 6.9 | 5.0 | 5.9 | 3.8 | 5.6 |
| Depreciation | 5.2 | 5.4 | 5.4 | 4.3 | 3.7 | 3.7 | 4.1 | 4.2 | 4.3 | 4.2 |
| Profit before tax | 14.0 | 8.1 | 7.5 | 5.2 | 5.2 | 9.4 | 9.7 | 10.9 | 12.4 | 2.5 |
| Tax % | -27.4% | -33.3% | -29.2% | -52.2% | -46% | -37% | -31.9% | 31.9% | 15.8% | -90.3% |
| Net Profit | 12.2 | 5.7 | 6.7 | 4.0 | 4.0 | 6.4 | 7.5 | 8.4 | 11.4 | 1.5 |
| EPS in Rs | 14.29 | 6.72 | 7.89 | 4.75 | 4.73 | 7.52 | 8.8 | 9.86 | 13.41 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 1% |
| 3 Years: | -7% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -8% |
| 1 Year: | -1% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -1% |
| 3 Years: | -11% |
| TTM: | 46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -8% |
| 1 Year: | -1% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|